Search Results
Your search for The ,The matches 34690 pages
Showing 32401 - 32450Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...
Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers
According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...
Sentinel Lymph Node Mapping Identifies Positive Lymph Nodes in Women With High-Risk Endometrial Cancer
In a study of women with high-grade endometrial cancer, researchers at The University of Texas MD Anderson Cancer Center found sentinel lymph node mapping accurately identified all women with node-positive, high-risk endometrial cancer, when prospectively compared to a complete pelvic and...
Addition of Bevacizumab to Chemotherapy Extends Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III study of women with ovarian cancer, researchers found that the addition of bevacizumab (Avastin) to standard chemotherapy extended median overall survival by 5 months compared to standard chemotherapy alone. The bevacizumab combination was also associated with a significant...
Italian Trial Shows Benefit of Dose-Dense Adjuvant Therapy With Sequential Epirubicin-Cyclophosphamide-Paclitaxel in Early Node-Positive Breast Cancer
In an Italian 2×2 phase III trial reported in The Lancet, Del Mastro et al found that dose-dense adjuvant therapy with sequential epirubicin, cyclophosphamide, and paclitaxel (EC-P) with or without fluorouracil (5-FU) increased disease-free survival vs standard-interval therapy in early-stage ...
Insufficient Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk
In a study reported in the Journal of Clinical Oncology, Rhodes et al found that only about half of screening-age women had awareness of breast density and adequate knowledge of its impact on breast cancer detection and risk. Breast density is an important factor contributing to false-negative...
ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline, Announce Opening of Public Comment Period
The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) today released a draft of a clinical practice guideline on the use of molecular marker testing for...
Panobinostat and Carfilzomib Combination Appears Safe and Effective in Relapsed/Refractory Multiple Myeloma
In patients with relapsed/refractory multiple myeloma, the combination of panobinostat (Farydak) and carfilzomib (Kyprolis) appears to be safe and effective, according to a phase I/II study by Berdeja et al in Haematologica. Further evaluation of this combination treatment is warranted to establish ...
Improved Outcome and Greater Use of Adjuvant Chemotherapy With Laparoscopic vs Open Colectomy in Nonmetastatic Colon Cancer
In a National Cancer Data Base analysis reported in the Journal of the National Cancer Institute, Zheng et al found that laparoscopic colectomy was associated with lower 30-day mortality, shorter length of stay, and, in patients with stage III disease, greater use of adjuvant chemotherapy vs open...
FDA Grants Priority Review to Carfilzomib Supplemental New Drug Application for Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted Amgen’s supplemental New Drug Application (sNDA) for carfilzomib (Kyprolis) injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the...
No Survival Benefit of IGF-1R/Insulin Receptor Inhibitor Linsitinib in Advanced Adrenocortical Carcinoma
In a phase III trial reported in The Lancet Oncology, Fassnacht et al found that linsitinib, an insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor inhibitor, did not improve overall survival vs placebo in patients with previously treated locally advanced or metastatic...
Women With Diabetes More Likely to be Diagnosed With Advanced-Stage Breast Cancer
Diabetes is associated with more advanced stage breast cancer, according to a new study by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital. The findings, published by Lipscombe et al in Breast Cancer Research and Treatment, confirm a strong link between diabetes...
Younger Men Who Survive 10 Years After Radical Prostatectomy Are More Likely to Die of Non–Cancer-Related Causes
A new study suggests that after radical prostatectomy for high-risk prostate cancer, both the age of the patient and the time survived since the operation have a significant impact on the cause of death. This means that, for young men with high-risk prostate cancer, doctors may have to reevaluate...
Low Nadir Testosterone in First Year of Hormone Therapy Linked to Improved Cause-Specific Survival and Delay of Hormone Resistance in Prostate Cancer
In an analysis from the PR-7 trial reported in the Journal of Clinical Oncology, Klotz et al found that in men with prostate cancer with biochemical failure after radiotherapy with or without surgery, a nadir serum testosterone level ≤ 0.7 nmol/L during the first year of continuous...
American Gastroenterological Association Releases New Guidelines on the Management of Asymptomatic Neoplastic Pancreatic Cysts
The growing use of sophisticated abdominal imaging techniques, which has led to a marked increase in the findings of incidental pancreatic cysts, has prompted the American Gastroenterological Association (AGA) to issue new recommendations in the management of asymptomatic neoplastic pancreatic...
Elevated C-Reactive Protein Associated With Poorer Outcome in Melanoma
In a study reported in the Journal of Clinical Oncology, Fang et al found that an elevated C-reactive protein level was associated with poorer overall and melanoma-specific survival in patients with melanoma and that sequential increases in C-reactive protein were associated with an increased risk...
Smokers Have Twice the Risk of Prostate Cancer Recurrence After Surgery as Never-Smokers
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research by Rieken et al presented at the European Association of Urology (EAU) 2015 Congress in Madrid (Abstract 508). In 2012,...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
Marked Increase in Fracture Risk in Patients Receiving Hematopoietic Stem Cell Transplantation
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Pundole et al found that patients undergoing hematopoietic stem cell transplantation are at increased risk of bone fracture later in life, with risk being particularly elevated in women and men aged 45 to 64...
Study Compares Incidence and Severity of Treatment-Related Neuropathy in Patients With Colorectal Cancer vs Other Cancers
Patients with colorectal cancer experience significantly higher rates of numbness/tingling but comparable neuropathic pain relative to patients with other cancers, according to a study by Lewis et al in the Journal of Pain and Symptom Management. In addition, numbness/tingling was more likely to be ...
Effect of Smoking and Alcohol Consumption on Feeding Tube Duration in Head and Neck Cancer Patients
Current smoking and heavy alcohol consumption appear to be risk factors for prolonged use of a gastrostomy tube in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy. The findings were published in a report by O’Shea et al in JAMA Otolaryngology-Head & Neck...
Genome-Wide CRISPR Screen Provides Better Understanding of Tumor Evolution and Metastasis
Scientists from the Broad Institute and the Koch Institute for Integrative Cancer Research at MIT used CRISPR-Cas9 gene-editing technology to “knock out,” or turn off, all genes across the genome systematically in a mouse model of non–small cell lung cancer cells and then tested...
New Surgical Algorithm Results in Improved Complete Resection Rates in Advanced Ovarian Cancer
A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor—a milestone strongly tied to improved chances of survival. The researchers describe...
Decline in Proportion of Lung Cancer Patients Meeting Screening Criteria
In a study reported in a research letter in JAMA, Wang et al found that the proportion of patients with lung cancer who would have met U.S. Preventive Services Task Force (USPSTF) criteria for low-dose computed tomography (CT) lung screening decreased significantly between the periods of 1984 to...
PET-Adapted Sequential Salvage Therapy With Brentuximab and Augmented ICE Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
In a phase II study reported in The Lancet Oncology, Moskowitz et al found that a salvage strategy involving brentuximab vedotin (Adcetris) treatment followed by 18F-fluorodeoxyglucose positron-emission tomography (PET) and augmented ifosfamide, carboplatin, and etoposide (ICE) in PET-positive...
No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL
In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...
Experts Explore the Reasons Behind the High Cost of Cancer Drugs in America
Increasingly high prices for cancer drugs are affecting patient care, as well as the health-care system overall, in the United States. These findings were published in a special article by Rajkumar and Kantarjian in the journal Mayo Clinic Proceedings. “Americans with cancer pay 50% to 100%...
Measuring Minimal Residual Disease Levels Proves to Be a Powerful Tool for Guiding Leukemia Treatment
According to a prospective study led by researchers at St. Jude Children's Research Hospital, measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may help boost survival of young leukemia patients by better matching patients with the right...
European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement
In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...
Vegetarian Dietary Pattern, Particularly Pescovegetarian Pattern, Is Associated With Reduced Risk of Colorectal Cancer
In a study reported by Orlich et al in JAMA Internal Medicine, a vegetarian dietary pattern was associated with a reduced risk of colorectal cancer, with risk reduction appearing to be greatest in pescovegetarians. Study Details The study involved data from 77,659 participants in the Adventist...
Preliminary Study Reveals Gene Regulatory Path as Target for Aggressive Pediatric Brain Cancer
Working with cells taken from children with a very rare but aggressive form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of genes, and may spur cancer cell growth and resistance to anticancer treatment. ...
Study Finds U.S. Spends More on Cancer Care but Saves Fewer Lives Than Western Europe
Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970. Researchers led by Samir Soneji, PhD, of Dartmouth's Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy & Clinical Practice...
Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site
In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....
Nivolumab Shows Activity in Advanced, Refractory Squamous NSCLC
In the phase II CheckMate 063 study reported in The Lancet Oncology, Rizvi et al found that the PD-1 inhibitor nivolumab (Opdivo) produced durable responses in some patients with advanced, refractory squamous non–small cell lung cancer (NSCLC) who had received at least two prior treatments....
Addition of Aprepitant to Ondansetron Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
In a phase III trial reported in The Lancet Oncology, Kang et al found that adding aprepitant to ondansetron with or without dexamethasone was effective in preventing chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately or highly emetogenic chemotherapy. Study...
Findings in Pooled Analysis of Long-Term Survival With Ipilimumab in Advanced Melanoma
In a pooled analysis reported in the Journal of Clinical Oncology, Schadendorf et al found 3-year overall survival rates of 26% and 20% in treatment-naive and previously treated patients receiving ipilimumab (Yervoy)-based treatment for unresectable or metastatic melanoma. A survival curve plateau...
New Breast Cancer Test Links Immune ‘Hotspots’ to Better Survival
Scientists have developed a new test that predicts the survival chances of women with breast cancer by analyzing images of “hotspots” where there has been a fierce immune reaction to a tumor. Using statistical software previously used in criminology studies of crime hotspots,...
NIH-Funded Study Suggests Novel Strategy to Improve Vaccine Efficacy in the Treatment of Glioblastoma
Although dendritic cell–based immunotherapy has shown limited promise in the treatment of patients with advanced cancers, including glioblastoma, the factors dictating dendritic cell–based vaccine efficacy have been poorly understood. Now, a clinical trial funded by the National...
Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma Defined by BRAF Mutation and CDKN2A Deletion
In a study reported in the Journal of Clinical Oncology, Mistry et al found that presence of BRAF V600E mutation and CDKN2A deletion defined a clinically distinct subtype of pediatric secondary high-grade glioma. BRAF V600E mutation was associated with a prolonged time to transformation. Study...
Goserelin Provides Ovarian Protection During Adjuvant Chemotherapy for Breast Cancer
In the phase III POEMS/S0230 trial reported in The New England Journal of Medicine, Moore et al found that treatment with the gonadotropin-releasing hormone agonist goserelin (Zoladex) reduced risk of ovarian failure during chemotherapy for breast cancer in premenopausal women. Study Details In...
Breast Cancer Risk May Increase in Women Who Have First-Degree Relatives With a History of Prostate Cancer
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. Researchers from multiple institutions published their findings in a study by Beebe-Dimmer et al in Cancer. The study's results indicate that clinicians should take a...
International Lymphoma Radiation Oncology Group Issues Treatment Guidelines for Pediatric Hodgkin Lymphoma
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of three-dimensional (3D) computed tomography (CT)–based radiation therapy planning and volumetric image guidance, specifically to more effectively treat pediatric Hodgkin lymphoma. The...
Reduced Mammography Rates 3 Years After 2009 U.S. Preventive Services Task Force Guidelines Changes
In a study reported in the Journal of Clinical Oncology, Wharam et al found that estimated mammography rates were lower than predicted in white, Hispanic, and Asian women since the U.S. Preventive Services Task Force (USPSTF) changed its screening recommendations in November 2009. The guidelines...
Outcomes of Phase II Basket Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In a basket trial (CUSTOM) reported in the Journal of Clinical Oncology, Lopez-Chavez et al performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer, or thymic malignancies and assigned those in any of five actionable...
Maintenance Sunitinib Improves Progression-Free Survival in Phase II Trial in Untreated Extensive-Stage Small Cell Lung Cancer
In the randomized phase II Cancer and Leukemia Group B (CALGB) 30504/Alliance trial reported in the Journal of Clinical Oncology, Ready et al found that sunitinib (Sutent) vs placebo maintenance following chemotherapy improved progression-free survival in patients with previously untreated...
Substitution of Bortezomib for Vincristine in R‑CHOP Improves Progression-Free Survival in First-Line Therapy for Mantle Cell Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Robak et al found that VR-CAP, a regimen replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone), significantly improved progression-free...
Chromosomal Rearrangement May Be the Key to Progress Against Aggressive Infant Leukemia
The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene. The findings, reported by Andersson et al ...
Annual ASCO Report Shows Widespread Disturbance in Oncology Practice, Amid Growing Patient Demand and Administrative Burden
The U.S. cancer care system faces tremendous turbulence while dealing with growing numbers of cancer patients and survivors, mounting pressures to control rising health-care costs, and widespread oncology practice transformation, reports a new study by the American Society of Clinical Oncology...
Palliative Care Consultation Associated With Less Aggressive End-of-Life Care in Advanced Pancreas Cancer
In a study reported in the Journal of the National Cancer Institute, Jang et al found that palliative care consultation was associated with decreased use of chemotherapy near death and lower risks of ICU admission, multiple emergency department visits, and multiple hospitalizations near death in...
